Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Vildagliptin
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Vildagliptin, Type 2 diabetes
Eligibility Criteria
Inclusion Criteria:
- Must be able to complete a 3-week wash-out of current anti-diabetic medication
- Cannot take any medications which may alter gastric motility except for cardiac medication at a stable dose
- Must discontinue beta-blockers and lipid lowering drugs
- Blood glucose criteria must be met
- BMI in the range 30-35
Exclusion Criteria:
- History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- Need for insulin within 3 months or patients on thiazolidinediones
- Patients taking a sulfonylurea or metformin who cannot safely discontinue medication for the duration of the study
- Significant concomitant disease or complications of diabetes
- Patients with any history of gastrointestinal surgery or positive gastrointestinal symptons
- High tryglycerides as defined by the protocol
- Smokers who cannot abstain from smoking during the treatment periods
Sites / Locations
- Novartis Pharmaceuticals
- Novartis Investigative Site
Outcomes
Primary Outcome Measures
To explore whether vildagliptin augments insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal in patients with type 2 diabetes
Secondary Outcome Measures
To measure the effects of vildagliptin on tissue carbohydrate metabolism (skeletal muscle)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00380445
Brief Title
Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes
Official Title
Effect of Vildagliptin on Adipose Tissue and Skeletal Muscle Metabolism in Obese Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
April 2007 (Actual)
Study Completion Date
April 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis
4. Oversight
5. Study Description
Brief Summary
Please note this study is not being conducted in the United States. The purpose of this study is to test the hypothesis that acute DPP-4 inhibition with vildagliptin improves fat and muscle metabolism in patients with type 2 diabetes mellitus.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Vildagliptin, Type 2 diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Vildagliptin
Primary Outcome Measure Information:
Title
To explore whether vildagliptin augments insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal in patients with type 2 diabetes
Secondary Outcome Measure Information:
Title
To measure the effects of vildagliptin on tissue carbohydrate metabolism (skeletal muscle)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Eligibility Criteria
Inclusion Criteria:
Must be able to complete a 3-week wash-out of current anti-diabetic medication
Cannot take any medications which may alter gastric motility except for cardiac medication at a stable dose
Must discontinue beta-blockers and lipid lowering drugs
Blood glucose criteria must be met
BMI in the range 30-35
Exclusion Criteria:
History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
Need for insulin within 3 months or patients on thiazolidinediones
Patients taking a sulfonylurea or metformin who cannot safely discontinue medication for the duration of the study
Significant concomitant disease or complications of diabetes
Patients with any history of gastrointestinal surgery or positive gastrointestinal symptons
High tryglycerides as defined by the protocol
Smokers who cannot abstain from smoking during the treatment periods
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Pharmaceuticals
City
East Hanover
State/Province
New Jersey
ZIP/Postal Code
07936
Country
United States
Facility Name
Novartis Investigative Site
City
Investigative Centers
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
19088168
Citation
Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009 Mar;94(3):846-52. doi: 10.1210/jc.2008-1400. Epub 2008 Dec 16.
Results Reference
result
Learn more about this trial
Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs